Elucidating Substrate and Inhibitor Binding Sites on the Surface of GSK-3β and the Refinement of a Competitive Inhibitor

被引:27
|
作者
Licht-Murava, Avital [1 ]
Plotkin, Batya [1 ]
Eisenstein, Miriam [2 ]
Eldar-Finkelman, Hagit [1 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel
[2] Weizmann Inst Sci, Dept Chem Res Support, IL-76100 Rehovot, Israel
关键词
protein kinase; molecular modeling; structure/function; inhibitors; drug design; parasite GSK-3; GLYCOGEN-SYNTHASE KINASE-3; INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE; PEPTIDE INHIBITORS; DRUG TARGET; PHOSPHORYLATION; GSK3; GLYCOGEN-SYNTHASE-KINASE-3; SPECIFICITY; MECHANISM;
D O I
10.1016/j.jmb.2011.02.036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A molecular understanding of substrate recognition of protein kinases provides an important basis for the development of substrate competitive inhibitors. Here, we explored substrate recognition and competitive inhibition of glycogen synthase kinase (GSK)-3 beta using molecular and computational tools. In previous work, we described Gln89 and Asn95 within GSK-3 beta as important substrates binding sites. Here, we show that the cavity bordered by loop 89-QDKRFICN-95, located in the vicinity of the GSK-3 beta catalytic core, is a promiscuous substrate binding subsite. Mutations within this segment highlighted Phe93 as an additional essential contact residue for substrates' recognition. However, unlike Gln89 and Asn95, Phe93 was also important for the binding of our previously described substrate competitive inhibitor, L803 [KEAPPAPPQS(p)P], and its cell-permeable variant L803-mts. The effects of the substitution of charged or polar residues within L803 further suggested that binding to GSK-3 beta is governed by hydrophobic interactions. Our computational model of GSK-3 beta bound to L803 was in agreement with the experimental data. It revealed L803 binding with a hydrophobic surface patch and identified interactions between Pro8 (L803) and Phe93 (GSK-3 beta). Computational modeling of new L803 variants predicted that inhibition would be strengthened by adding contacts with Phe93 or by increasing the hydrophobic content of the peptide. Indeed, the newly designed L803 variants showed improved inhibition. Our study identified different and overlapping elements in GSK-3 beta substrate and inhibitor recognition and provides a novel example for model-based rational design of substrate competitive inhibitors for GSK-3. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:366 / 378
页数:13
相关论文
共 50 条
  • [21] Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity
    Arfeen, Minhajul
    Patel, Rahul
    Khan, Tosif
    Bharatam, Prasad V.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2015, 33 (12) : 2578 - 2593
  • [22] A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
    Sereno, L.
    Coma, M.
    Rodriguez, M.
    Sanchez-Ferrer, P.
    Sanchez, M. B.
    Gich, I.
    Agullo, J. M.
    Perez, M.
    Avila, J.
    Guardia-Laguarta, C.
    Clarimon, J.
    Lleo, A.
    Gomez-Isla, T.
    NEUROBIOLOGY OF DISEASE, 2009, 35 (03) : 359 - 367
  • [23] In silico interaction studies of first dual inhibitor against BACE-1/GSK-3β
    Kumar, Akhil
    Srivastava, Gaurava
    Sharma, Ashok
    2016 INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND SYSTEMS BIOLOGY (BSB), 2016,
  • [24] Disparate Effects of Lithium and a GSK-3 Inhibitor on Neuronal Oscillatory Activity in Prefrontal Cortex and Hippocampus
    Tuan Nguyen
    Fan, Theresa
    George, Susan R.
    Perreault, Melissa L.
    FRONTIERS IN AGING NEUROSCIENCE, 2018, 9
  • [25] Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1
    Lewis-Ballester, Ariel
    Pham, Khoa N.
    Batabyal, Dipanwita
    Karkashon, Shay
    Bonanno, Jeffrey B.
    Poulos, Thomas L.
    Yeh, Syun-Ru
    NATURE COMMUNICATIONS, 2017, 8
  • [26] Design, synthesis and anti-AD effects of dual inhibitor targeting glutaminyl cyclase/GSK-3?
    Xie, Yazhou
    Chen, Chen
    Lin, Shujing
    Yu, Xi
    Ye, Shuixian
    Chen, Xiaojie
    Ouyang, Na
    Xiong, Wei
    Li, Chenyang
    Xu, Chenshu
    Song, Guoli
    Wu, Haiqiang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 248
  • [27] Beryllium is an inhibitor of cellular GSK-3β that is 1,000-fold more potent than lithium
    Mudireddy, Swapna R.
    Abdul, Ataur Rahman Mohammed
    Gorjala, Priyatham
    Gary, Ronald K.
    BIOMETALS, 2014, 27 (06) : 1203 - 1216
  • [28] Beryllium is an inhibitor of cellular GSK-3β that is 1,000-fold more potent than lithium
    Swapna R. Mudireddy
    Ataur Rahman Mohammed Abdul
    Priyatham Gorjala
    Ronald K. Gary
    BioMetals, 2014, 27 : 1203 - 1216
  • [29] Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells
    Yu, Ai-Song
    Zhao, Lin
    TUMOR BIOLOGY, 2016, 37 (04) : 4857 - 4864
  • [30] GSK-3β inhibitor 6-bromo-indirubin-3'-oxime promotes both adhesive activity and drug resistance in colorectal cancer cells
    Liu, Kunping
    Li, Jinbang
    Wu, Xuefang
    Chen, Meixiang
    Luo, Feng
    Li, Jun
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 51 (06) : 1821 - 1830